Skip to search formSkip to main contentSkip to account menu

HMPL-013

Known as: VEGFR-1/2/3 Inhibitor HMPL-013 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzofuransQuinazolines

Narrower (1)

fruquintinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The clinical application of fruquintinib on colorectal cancer
ABSTRACT Introduction: Anti-angiogenetic agents are currently the most commonly used drugs for the treatment of colorectal cancer… 
2017
2017
A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers
PurposeFruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular… 
2016
2016
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with…
PurposeFruquintinib (HMPL-013) is a novel oral small molecule compound that selectively inhibits vascular endothelial growth… 
2014
2014
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
AbstractPurpose This study evaluated the preclinical pharmacokinetics (PK) and disposition of Fruquintinib (HMPL-013), a small… 
2014
2014
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies. One challenging… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License